Simvastatin prevents neuroinflammation by inhibiting N-methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells

Journal of Neuroscience Research

Volumn 92, Issue 5, 2014, Pages 634-640

  Yan, Junqiang ^a   Sun, Jiachun ^a   Huang, Lina ^a   Fu, Qizhi ^a   Du, Ganqin ^a  

^a Department of Neurology The First Affiliated Hospital of He Nan University of Science and Technology   (China)

Author keywords

Neuroinflammation; NMDA receptor 1; Parkinson's disease; Simvastatin

Indexed keywords

GLUTAMIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; OXIDOPAMINE; SIMVASTATIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; PC12 CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

NEUROINFLAMMATION; NMDA RECEPTOR 1; PARKINSON'S DISEASE; SIMVASTATIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; L-LACTATE DEHYDROGENASE; OXIDOPAMINE; PC12 CELLS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIMVASTATIN; SYMPATHOLYTICS; TIME FACTORS;

EID: 84895920292     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23329     Document Type: Article

References (32)

1. Armentero MT, Fancellu R, Nappi G, Bramanti P, Blandini F. 2006. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis 22:1-9.
2. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. 2005. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196:422-429.
3. de Bartolomeis A, Fiore G, Iasevoli F. 2005. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 11:3561-3594.
4. Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C. 2006. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 69:805-812.
5. Hallett PJ, Standaert DG. 2004. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102:155-174.
6. Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW. 2006. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci 26:4690-4700.
7. Janssen WG, Vissavajjhala P, Andrews G, Moran T, Hof PR, Morrison JH. 2005. Cellular and synaptic distribution of NR2A and NR2B in macaque monkey and rat hippocampus as visualized with subunit-specific monoclonal antibodies. Experimental neurology 191(Suppl 1):S28-S44.
8. Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS. 2013. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 81:410-416.
9. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. 2004. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis 15:80-92.
10. Nandhu MS, Paul J, Kuruvila KP, Abraham PM, Antony S, Paulose CS. 2011. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA. Mol Cell Biochem 353:47-57.
11. Nilsson A, Eriksson M, Muly EC, Akesson E, Samuelsson EB, Bogdanovic N, Benedikz E, Sundstrom E. 2007. Analysis of NR3A receptor subunits in human native NMDA receptors. Brain Res 1186:102-112.
12. Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X. 2012. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 9:746-758.
13. Patti G, Tomai F, Melfi R, Ricottini E, Macri M, Sedati P, Giardina A, Aurigemma C, Leporace M, D'Ambrosio A, Di Sciascio G. 2013. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. J Am Coll Cardiol 61:1379-1387.
14. Ramos MC, Sierra S, Ramirez C, Velasco J, Burgos JS. 2012. Simvastatin modulates the Alzheimer's disease-related gene seladin-1. J Alzheimers Dis 28:297-301.
15. Riquelme E, Abarca J, Campusano JM, Bustos G. 2012. An NR2B-dependent decrease in the expression of trkB receptors precedes the disappearance of dopaminergic cells in substantia nigra in a rat model of presymptomatic Parkinson's disease. Parkinsons Dis 2012:129605.
16. Rodriguez-Blanco J, Martín V, Herrera F, García-Santos G, Antolín I, Rodriguez C. 2008. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 107:127-140.
17. Sgambato-Faure V, Cenci MA. 2012. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 96:69-86.
18. Shen Y, Fan Y, Dai H, Fu Q, Hu W, Chen Z. 2007a. Neuroprotective effect of carnosine on necrotic cell death in PC12 cells. Neurosci Lett 414:145-149.
19. 3 receptors. Biochem Pharmacol 73:709-717.
20. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS. 2011. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23:307-318.
21. Tapia-Perez JH, Rupa R, Zilke R, Gehring S, Voellger B, Schneider T. 2013. Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. Neurosurg Rev 36:279-287; discussion 287.
22. Undela K, Gudala K, Malla S, Bansal D. 2013. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol 260:158-165.
23. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. 2009. Statins: mechanisms of neuroprotection. Prog Neurobiol 88:64-75.
24. Vazhappilly R, Wee KS, Sucher NJ, Low CM. 2010. A non-muscle myosin II motor links NR1 to retrograde trafficking and proteasomal degradation in PC12 cells. Neurochem Int 56:569-576.
25. Wang C, Anastasio N, Popov V, LeDay A, Johnson KM. 2004. Blockade of N-methyl-D-aspartate receptors by phencyclidine causes the loss of corticostriatal neurons. Neuroscience 125:473-483.
26. Wang WY, Wang H, Luo Y, Jia LJ, Zhao JN, Zhang HH, Ma ZW, Xue QS, Yu BW. 2012. The effects of metabotropic glutamate receptor 7 allosteric agonist N, N′-dibenzhydrylethane-1, 2-diamine dihydrochloride on developmental sevoflurane neurotoxicity: role of extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase signaling pathway. Neuroscience 205:167-177.
27. Xia P, Chen HS, Zhang D, Lipton SA. 2010. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 30:11246-11250.
28. Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, Xiong Z, Deng C, Huang XF, Yenari MA, Yang YG, Ying W, Wang Q. 2011. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One 6:e20945.
29. + efflux and neuronal apoptosis. Science 284:336-339.
30. Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S. 2013. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol 43:281-289.
31. Zhu G, Huang Y, Chen Y, Zhuang Y, Behnisch T. 2012. MPTP modulates hippocampal synaptic transmission and activity-dependent synaptic plasticity via dopamine receptors. J Neurochem 122:582-593.
32. Zold CL, Escande MV, Pomata PE, Riquelme LA, Murer MG. 2012. Striatal NMDA receptors gate cortico-pallidal synchronization in a rat model of Parkinson's disease. Neurobiol Dis 47:38-48.